Skip to main content

Editors' pick

06-08-2017 | NSAIDs | Editorial | Article

Cardiovascular risk of non-steroidal anti-inflammatory drugs

Editorial Board member Oliver FitzGerald reviews the cardiovascular risk of non-steroidal anti-inflammatory drugs such as celecoxib, naproxen, and ibuprofen in light of results from the PRECISION study.

06-05-2017 | Rheumatoid arthritis | Feature | Article

JAK inhibitors: The next generation of drugs for treating rheumatoid arthritis?

medwireNews takes a look at the efficacy and safety profiles of JAK inhibitors for the treatment of rheumatoid arthritis, and addresses some common questions about their use.

05-24-2017 | Gout | Editorial | Article

Taking gout seriously

Gout is prevalent in developed countries but does not receive the same investment as conditions such as rheumatoid arthritis. Editorial Board member Fernando Pérez-Ruiz suggests that rheumatologists and healthcare providers need to start taking gout seriously.

Latest from across the site

06-23-2017 | Rheumatoid arthritis | News

Dose reduction of TNF inhibitors a ‘reasonable long-term approach’ for RA patients

The efficacy and safety profiles of disease activity-guided dose reduction of tumor necrosis factor inhibitors are maintained for up to 3 years in patients with rheumatoid arthritis, follow-up results of the DRESS study suggest.


Ann Rheum Dis 2017; Advance online publication

06-22-2017 | Rheumatoid arthritis | News

Support for adding tofacitinib to methotrexate in patients with RA

Results of the ORAL Strategy trial suggest that tofacitinib given in combination with methotrexate, but not alone, is noninferior to adalimumab plus methotrexate for the treatment of patients with rheumatoid arthritis and an inadequate response to methotrexate.


Lancet 2017; Advance online publication

06-21-2017 | Gout | Conference report | Article

EULAR 2017

Exploring the links between obesity and musculoskeletal disorders

Presentations on the final day of EULAR 2017 examined the relationship between diet, obesity, and rheumatologic diseases.

06-20-2017 | Rheumatoid arthritis | Conference report | Article

EULAR 2017

Reassuring findings on cancer risk in RA patients prescribed bDMARDs

 Findings from the ARTIS study group suggest that biologic disease-modifying antirheumatic drugs and tumor necrosis factor inhibitors are not associated with an increased overall cancer risk compared with conventional synthetic DMARDs.

06-20-2017 | Osteoarthritis | Conference report | Article

EULAR 2017

Further development of novel OA drugs supported

Phase II trial results presented at the Annual European Congress of Rheumatology (EULAR) 2017 support the efficacy of two new compounds for the treatment of osteoarthritis (OA).

06-19-2017 | Rheumatoid arthritis | EULAR 2017 | News

EULAR 2017

Surprise findings for early high-dose glucocorticoids in RA treatment

The addition of high-dose glucocorticoids to first-line adalimumab and methotrexate in the treatment of rheumatoid arthritis fails to further improve efficacy, results of a phase IV study show.

Latest from us on Twitter

Meet our Editorial Board

image credits